Skip to: Content
Skip to: Site Navigation
Skip to: Search

FRIDAY, NOVEMBER 27, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter

PREMIUM NEWS ARCHIVE

Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer.

Article from: Cancer Weekly Article date: March 31, 2009

Medivation, Inc. (NASDAQ:MDVN) announced that it has received written permission from the U.S. Food and Drug Administration (FDA) to begin a pivotal Phase 3 trial of MDV3100, its novel androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed docetaxel-based chemotherapy. The placebo-controlled, double-blind, multinational trial will enroll approximately 1,200 patients who will be randomized (2:1) to receive either MDV3100 or placebo. The primary endpoint of the trial will ...

Read full article   (with a Free Trial at HighBeam Research)
Newser gathers stories from across the web and packs what you need to know into about 120 words. Check out these stories related to your search.
Visit our grid for the latest news.